EXAS vs GERN · rev $2.76B vs rev $109.3M
EXACT Sciences Corporation (EXAS) versus Geron Corporation (GERN) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Geron Corporation (GERN) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported GERN revenue for 2026-06-30 was $109.3M. Net income was -$20.3M. GERN currently screens at market cap $878.9M.
EXAS currently screens at market cap $20.03B. GERN currently screens at market cap $878.9M.
Not investment advice. Open the EXAS and GERN stock pages for the full models.
Not investment advice.